222 related articles for article (PubMed ID: 22044661)
1. Effect of 12 months of testosterone replacement therapy on metabolic syndrome components in hypogonadal men: data from the Testim Registry in the US (TRiUS).
Bhattacharya RK; Khera M; Blick G; Kushner H; Nguyen D; Miner MM
BMC Endocr Disord; 2011 Nov; 11():18. PubMed ID: 22044661
[TBL] [Abstract][Full Text] [Related]
2. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
[TBL] [Abstract][Full Text] [Related]
3. Testosterone replacement therapy among elderly males: the Testim Registry in the US (TRiUS).
Bhattacharya RK; Khera M; Blick G; Kushner H; Miner MM
Clin Interv Aging; 2012; 7():321-30. PubMed ID: 22956867
[TBL] [Abstract][Full Text] [Related]
4. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
Blick G
Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
[TBL] [Abstract][Full Text] [Related]
5. The effect of testosterone supplementation on depression symptoms in hypogonadal men from the Testim Registry in the US (TRiUS).
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
Aging Male; 2012 Mar; 15(1):14-21. PubMed ID: 22092151
[TBL] [Abstract][Full Text] [Related]
6. 12-month observation of testosterone replacement effectiveness in a general population of men.
Miner MM; Bhattacharya RK; Blick G; Kushner H; Khera M
Postgrad Med; 2013 Mar; 125(2):8-18. PubMed ID: 23816767
[TBL] [Abstract][Full Text] [Related]
7. Testosterone replacement therapy in men with hypogonadism and HIV/AIDS: results from the TRiUS registry.
Blick G; Khera M; Bhattacharya RK; Kushner H; Miner MM
Postgrad Med; 2013 Mar; 125(2):19-29. PubMed ID: 23816768
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
[TBL] [Abstract][Full Text] [Related]
9. Changes in prostate specific antigen in hypogonadal men after 12 months of testosterone replacement therapy: support for the prostate saturation theory.
Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
J Urol; 2011 Sep; 186(3):1005-11. PubMed ID: 21788049
[TBL] [Abstract][Full Text] [Related]
10. Total testosterone levels are correlated to metabolic syndrome components.
Blaya R; Thomaz LD; Guilhermano F; Paludo Ade O; Rhoden L; Halmenschlager G; Rhoden EL
Aging Male; 2016 Jun; 19(2):85-9. PubMed ID: 26961662
[TBL] [Abstract][Full Text] [Related]
11. Testosterone replacement therapy outcomes among opioid users: the Testim Registry in the United States (TRiUS).
Blick G; Khera M; Bhattacharya RK; Nguyen D; Kushner H; Miner MM
Pain Med; 2012 May; 13(5):688-98. PubMed ID: 22536837
[TBL] [Abstract][Full Text] [Related]
12. Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies.
Brand JS; Rovers MM; Yeap BB; Schneider HJ; Tuomainen TP; Haring R; Corona G; Onat A; Maggio M; Bouchard C; Tong PC; Chen RY; Akishita M; Gietema JA; Gannagé-Yared MH; Undén AL; Hautanen A; Goncharov NP; Kumanov P; Chubb SA; Almeida OP; Wittchen HU; Klotsche J; Wallaschofski H; Völzke H; Kauhanen J; Salonen JT; Ferrucci L; van der Schouw YT
PLoS One; 2014; 9(7):e100409. PubMed ID: 25019163
[TBL] [Abstract][Full Text] [Related]
13. Effects of testosterone replacement therapy on metabolic syndrome among Japanese hypogonadal men: A subanalysis of a prospective randomised controlled trial (EARTH study).
Shigehara K; Konaka H; Nohara T; Izumi K; Kitagawa Y; Kadono Y; Iwamoto T; Koh E; Mizokami A; Namiki M
Andrologia; 2018 Feb; 50(1):. PubMed ID: 28497534
[TBL] [Abstract][Full Text] [Related]
14. [The relationship between testosterone deficiency and metabolic syndrome in obese men].
Tylińska M; Broncel M
Pol Merkur Lekarski; 2013 Jan; 34(199):24-8. PubMed ID: 23488280
[TBL] [Abstract][Full Text] [Related]
15. Testosterone, sex hormone-binding globulin and the metabolic syndrome: a systematic review and meta-analysis of observational studies.
Brand JS; van der Tweel I; Grobbee DE; Emmelot-Vonk MH; van der Schouw YT
Int J Epidemiol; 2011 Feb; 40(1):189-207. PubMed ID: 20870782
[TBL] [Abstract][Full Text] [Related]
16. Total testosterone is the most valuable indicator of metabolic syndrome among various testosterone values in middle-aged Japanese men.
Tanabe M; Akehi Y; Nomiyama T; Murakami J; Yanase T
Endocr J; 2015; 62(2):123-32. PubMed ID: 25342164
[TBL] [Abstract][Full Text] [Related]
17. Lower levels sex hormone-binding globulin independently associated with metabolic syndrome in pre-elderly and elderly men in China.
Pang XN; Hu Y; Yuan Y; Shen JP; Zha XY; Sun X
J Geriatr Cardiol; 2013 Mar; 10(1):28-33. PubMed ID: 23610571
[TBL] [Abstract][Full Text] [Related]
18. Testosterone Replacement Therapy and Components of the Metabolic Syndrome.
Anaissie J; Roberts NH; Wang P; Yafi FA
Sex Med Rev; 2017 Apr; 5(2):200-210. PubMed ID: 28202344
[TBL] [Abstract][Full Text] [Related]
19. Testosterone replacement therapy improves insulin sensitivity and decreases high sensitivity C-reactive protein levels in hypogonadotropic hypogonadal young male patients.
Wu XY; Mao JF; Lu SY; Zhang Q; Shi YF
Chin Med J (Engl); 2009 Dec; 122(23):2846-50. PubMed ID: 20092788
[TBL] [Abstract][Full Text] [Related]
20. Absorption of testosterone gel 1% (Testim) from three different application sites.
Guay AT; Smith TM; Offutt LA
J Sex Med; 2009 Sep; 6(9):2601-10. PubMed ID: 19549089
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
